introduction to pharmac and pharmacoeconomics
TRANSCRIPT
![Page 1: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/1.jpg)
Introduction to Pharmac and Pharmacoeconomics
![Page 2: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/2.jpg)
PHARMAC’s role and mission
“…to secure for eligible people in need of pharmaceuticals,
the best health outcomes that are reasonably achievable
from pharmaceutical treatment and from within the
amount of funding provided.”
• New Zealand Public Health and Disability Act 2000
![Page 3: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/3.jpg)
Our operating environment
![Page 4: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/4.jpg)
Health budget
$16 billion each year
Hospital medical devices: $650 million
Hospital medicines: $200 million
Community medicines budget: $870 million
![Page 5: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/5.jpg)
Spoiler alert
![Page 6: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/6.jpg)
Ranking of Proposals
Priority Proposal IndicationPTAC
priority
CUA
rank
QALYs per
$1m, likely
(possible)
Proposal
expenditure (first
year)
Cumulative
expenditure
1 Fantasticol Lupus High 140-80
(20-100) $80,000 $0.1m
2 ColomabColorectal
cancerMedium 2
25-50
(15-50) $5,000,000 $5.1m
3 RheumatolRheumatic
feverHigh 6
5-10
(3-10) $1,000,000 $6.1m
4 Findaliptin Diabetes High 55-12
(2-20) $530,000 $6.6m
5 Vinedronate Arthritis High 47-10
(6-12) $1,200,000 $7.8m
6 Metogrel ACS Low 37-13
(4-16) $620,000 $8.4m
7 Tagaliptin Diabetes High 74-8
(0-10) $500,000 $8.9m
![Page 7: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/7.jpg)
Pharmacoeconomics within PHARMAC’s Decision making
process
![Page 8: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/8.jpg)
• “To secure for eligible people in need of pharmaceuticals, the best
health outcomes that can reasonably be achieved, and from within
the amount of funding provided.”
• New Zealand Public Health and Disability Act 2000
• “To secure for eligible people in need of pharmaceuticals, the best
health outcomes that can reasonably be achieved, and from within
the amount of funding provided.”
• Econ 101
![Page 9: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/9.jpg)
The decision making process
![Page 10: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/10.jpg)
Getting clinical advice into our decision-making
![Page 11: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/11.jpg)
Types of economic analysis
• Cost Benefit Analysis - CBA
• Cost Effectiveness Analysis - CEA
• Cost Consequence analysis - CCA
• Cost Minimization Analysis - CMA
• Cost Utility Analysis - CUA
• Budget Impact assessment - BIA
![Page 12: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/12.jpg)
Inputs into a CUA
Cost of the
proposal
Cost of the
status quoNet Cost
Health
gains of the
proposal
Health
gains of the
status quo
Net
Health
gains
less =
less =
Cost per
QALY=
![Page 13: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/13.jpg)
Four key bits for both intervention and comparator
• Health states
• Transition probabilities
• Health Gains
• Costs
![Page 14: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/14.jpg)
A simple model
![Page 15: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/15.jpg)
A complex model
![Page 16: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/16.jpg)
Moving between states: Transition probabilities
![Page 17: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/17.jpg)
Status Quo Proposal
92%96%
3%
5%
1%
3%
![Page 18: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/18.jpg)
Increasing QALYs through improving QOL/survival
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Year
Hea
lth
-rela
ted q
ua
lity o
f lif
e (
score
0 to
1.0
)
intervention
comparator
improved health-related quality of life
increased life expectancy
![Page 19: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/19.jpg)
Health Related Quality of Life (HR-QoL) - EQ5D
• Mobility
• 1. No problems walking around
• 2. Some problems walking around
• 3. Confined to bed
• Self-Care
• 1. No problems with self care (washing and dressing)
• 2. Some problems with washing and dressing
• 3. Unable to wash or dress
• Usual activities
• 1. No problems with performing usual activities
• 2. Some problems with performing usual activities
• 3. Unable to perform usual activities
• Pain/Discomfort
• 1. No pain or discomfort
• 2. Moderate pain or discomfort
• 3. Extreme pain or discomfort
• Anxiety/Depression
• 1. Not anxious or depressed
• 2. Moderately anxious or depressed
• 3. Extremely anxious or depressed
Health State: 11111
Qol: 1
Health State: 11212
QoL: 0.690
![Page 20: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/20.jpg)
Valuing health states
![Page 21: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/21.jpg)
Pharmaceutical costs
• Price of pharmaceutical
• Include any rebate
• Include future generic prices
• Include price movements
• Dose of pharmaceutical
• Dose should be based on dose used in clinical practice providing there is evidence of efficacy at the proposed dose
• Include any dose adjustments
• Associated pharmaceutical costs
• Include dispensing fees and pharmacy mark-up
• Include administration cost
![Page 22: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/22.jpg)
Health Sector Costs
Hospital costs estimated using
Diagnostic Related Group (DRG)
prices
Outpatient costs
• Outpatient clinic appointments
• Laboratory and diagnostic tests
• Nursing services
• Hospital-based outpatient programs
![Page 23: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/23.jpg)
Patient Costs
• Include direct patient healthcare costs that are at least partially
subsidised by government
• General Practitioner visits
• Pharmaceutical co-payments
• Home or continuing care
• Indirect patient costs not included
![Page 24: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/24.jpg)
Inputs into a CUA
Cost of the
proposal
Cost of the
status quoNet Cost
Health
gains of the
proposal
Health
gains of the
status quo
Net
Health
gains
less =
less =
Cost per
QALY=
Now we have this
![Page 25: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/25.jpg)
CUA rank
CUA Rank
QALYs per
Million
invested
Budget
impact
Drug A 1 20 $2m
Drug B 2 10 $4m
Drug C 3 8 $7m
Drug D 4 4 $15m
Drug E 5 2 $65m
$50,000 per QALY = 20 QALYs per million
![Page 26: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/26.jpg)
Are we at best yet?
![Page 27: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/27.jpg)
Factors for consideration
![Page 28: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/28.jpg)
![Page 29: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/29.jpg)
Health Need Proportional loss
-0.085
1
0 10 20 30 40 50 60 70 80 90 100
QoL
Age
![Page 30: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/30.jpg)
Ranking of proposals
Proposal Indication PTAC priority Health need CUA rankQALYs per $1m,
likely (possible)
Proposal
expenditure (first
year)
Cumulative expenditure
Fantasticol Lupus High High 1 40-80$80,000 $0.1m
ColomabColorectal
cancerMedium High 2 25-50
$5,000,000 $5.1m
RheumatolRheumatic
feverHigh High 6
5-10
$1,000,000 $6.1m
Findaliptin Diabetes High Low 5 5-12$530,000 $6.6m
Vinedronate Arthritis High Medium 4 7-10$1,200,000 $7.8m
Metogrel ACS Low Low 3 7-13$620,000 $8.4m
Tagaliptin Diabetes High Low 7 4-8$500,000 $8.9m
![Page 31: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/31.jpg)
Are we at best yet?
![Page 32: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/32.jpg)
The practical and strategic still matter. You still use judgement.
![Page 33: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/33.jpg)
Monitor Outcomes
![Page 34: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/34.jpg)
Source: Lancet 2017; 390: 231–66
![Page 35: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/35.jpg)
NZ Pharmaceutical spending, 1978-2013
![Page 36: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/36.jpg)
Overall spending on health is in line with the OECD averages
![Page 37: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/37.jpg)
Expenditure InternationallySource - University of Auckland
![Page 38: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/38.jpg)
Generics share
Share of
Prescriptions
Value of sales Source
Australia (2009) 30% 10-15% Löfgren et al
Southern Med
Review (2009) 2;
2:24-28
New Zealand (2013) 77% 34% OECD Health at a
glance
![Page 39: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/39.jpg)
Case Study – Fluconazole 200 mg (per pack)
1993 2005 2009
$628
$41.50$19.05
$1.9
million
![Page 40: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/40.jpg)
PHARMAC’s management model
Competition
e.g. Generics
New Medicines
Savings
re-investment
in the sector
![Page 41: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/41.jpg)
Those in greatest needs get most of the funds
![Page 42: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/42.jpg)
![Page 43: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/43.jpg)
Cost of cancer medicines, compared to overall spending
![Page 44: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/44.jpg)
We make comparisons
![Page 45: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/45.jpg)
Overall survival gains relative to NZ funded comparator
![Page 46: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/46.jpg)
PHARMAC’s role and mission
“…to secure for eligible people in need of pharmaceuticals,
the best health outcomes that are reasonably achievable
from pharmaceutical treatment and from within the
amount of funding provided.”
• New Zealand Public Health and Disability Act 2000
![Page 47: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/47.jpg)
Are we at best yet?
![Page 48: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/48.jpg)
Getting a sense of scale
• Identify sources of death and disability
• Determine what is amenable to change
![Page 49: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/49.jpg)
121128
0
20
40
60
80
100
120
140
Australia New Zealand
Age Standardised Cancer Deaths per 100k poeple
343 additional deaths
Source: https://vizhub.healthdata.org/gbd-compare/
![Page 50: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/50.jpg)
Relative risk = 1.79https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-mana-hauora-tutohu-health-status-indicators/cancer
![Page 51: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/51.jpg)
New Zealand has 128 Cancer deaths per 100k
Maori Relative risk of death is 1.79
% of
Population
Death rate per
100k
Share of total
deaths
Total deaths
Maori 15% 204 31 31+ 97 = 128
Non-Maori 85% 114 97
Difference in death rate is 90
Source: Own calculations. Age Standardised.
![Page 52: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/52.jpg)
0
10
20
30
40
50
60
70
80
90
100
Difference between Maori andnon-maori on cancer deaths
Difference between Aus and NZon Cancer deaths
Why scale is important
![Page 53: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/53.jpg)
"Approximately 90% of cancers that are cured are cured by
surgery and radiation" - Richard Sullivan, Professor of Cancer
and Global Health, Kings college London
![Page 54: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/54.jpg)
Causes of deathDisease Women Men TotalIschemic heart disease 16% 20% 37%
Alzheimer's disease and other dementias 12% 6% 18%
Chronic obstructive pulmonary disease 6% 6% 11%
Tracheal, bronchus, and lung cancer 5% 6% 11%Colon and rectum cancer 5% 5% 10%Ischemic stroke 5% 3% 8%Intracerebral hemorrhage 3% 2% 6%Breast cancer 5% 0% 5%Lower respiratory infections 2% 2% 4%Prostate cancer 0% 4% 4%Atrial fibrillation and flutter 2% 1% 4%Falls 2% 2% 3%Pancreatic cancer 2% 2% 3%Diabetes mellitus type 2 1% 2% 3%Self-harm 1% 2% 3%
Chronic kidney disease due to diabetes mellitus type 2 1% 1% 3%
![Page 55: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/55.jpg)
![Page 56: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/56.jpg)
Source: https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-mana-hauora-tutohu-health-status-
indicators/cardiovascular-disease
Relative risk = 2.16
![Page 57: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/57.jpg)
New Zealand also has 128 Cardiovascular deaths per 100k
Maori Relative risk of death is 2.16
% of
Population
Death rate per
100k
Share of total
deaths
Total deaths
Maori 15% 235 35 35+ 93 = 128
Non-Maori 85% 109 93
Difference in death rate is 126
![Page 58: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/58.jpg)
0
50
100
150
200
250
Difference between Maori and non-maori Difference between Aus and NZ
Age Standardised death rate per 100k per annum
Cancer Cardiovascular
![Page 59: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/59.jpg)
What is amenable to change?
![Page 60: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/60.jpg)
New Strategy Launched 3 July 2017
Inequities Savings Systems
...by 2025...
![Page 61: Introduction to Pharmac and Pharmacoeconomics](https://reader030.vdocuments.us/reader030/viewer/2022012804/61bd2f5361276e740b102bea/html5/thumbnails/61.jpg)
Questions?